Dr. Bukhari is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
810 Bestgate Road
Suite 400
Annapolis, MD 21401Phone+1 410-897-6200Fax+1 410-266-7636
Education & Training
- University of MarylandFellowship, Hematology and Medical Oncology, 2017 - 2020
- Wright-Patterson Medical CenterChief Residency, Internal Medicine, 2016 - 2017
- Wright State UniversityResidency, Internal Medicine, 2013 - 2016
- Eastern Virginia Medical SchoolClass of 2013
Certifications & Licensure
- MD State Medical License 2017 - 2026
- VA State Medical License 2014 - 2022
- OH State Medical License 2013 - 2016
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 54 citationsImmune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes.Noa G. Holtzman, Hao Xie, Søren M. Bentzen, Vivek Kesari, Ali Bukhari
Neuro-Oncology. 2021-01-30 - 25 citationsRapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen lossAli Bukhari, Firas El Chaer, Rima Koka, Zeba N. Singh, Elizabeth Hutnick
American Journal of Hematology. 2019-10-01 - 2 citationsTimeliness of Lung Cancer Diagnosis and Treatment.Ali Bukhari, Geetika Kumar, Radhika Rajsheker, Ronald J. Markert
Federal Practitioner. 2017-02-01
Abstracts/Posters
- Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-...Ali Bukhari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predicti...Ali Bukhari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: